AR134149A1 - Proteínas de unión al receptor de transferrina y usos de estas - Google Patents

Proteínas de unión al receptor de transferrina y usos de estas

Info

Publication number
AR134149A1
AR134149A1 ARP240102829A ARP240102829A AR134149A1 AR 134149 A1 AR134149 A1 AR 134149A1 AR P240102829 A ARP240102829 A AR P240102829A AR P240102829 A ARP240102829 A AR P240102829A AR 134149 A1 AR134149 A1 AR 134149A1
Authority
AR
Argentina
Prior art keywords
binding proteins
tfr
conjugates
receptor binding
transferrin receptor
Prior art date
Application number
ARP240102829A
Other languages
English (en)
Inventor
Alberto Alvarado
Jeffrey Streetman Boyles
David Albert Driver
Daniel Scott Girard
Wendy Loza Hobbs
Jeff S Mdermott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR134149A1 publication Critical patent/AR134149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente descripción se proporcionan proteínas que comprenden proteína de unión al TfR, conjugados que comprenden tales proteínas de unión al TfR, p. ej., conjugados de proteínas de unión al TfRS-ARNbc, composiciones farmacéuticas que comprenden proteínas de unión al TfR o conjugados, y métodos para tratar enfermedades del SNC (p. ej., enfermedad neurodegenerativa) usando proteínas de unión al TfR o conjugados. También se incluyen métodos para tratar o reducir el dolor.
ARP240102829A 2023-10-18 2024-10-18 Proteínas de unión al receptor de transferrina y usos de estas AR134149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363591314P 2023-10-18 2023-10-18

Publications (1)

Publication Number Publication Date
AR134149A1 true AR134149A1 (es) 2025-12-03

Family

ID=93333932

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102829A AR134149A1 (es) 2023-10-18 2024-10-18 Proteínas de unión al receptor de transferrina y usos de estas

Country Status (10)

Country Link
KR (1) KR20260091558A (es)
CN (1) CN122422354A (es)
AR (1) AR134149A1 (es)
AU (1) AU2024362819A1 (es)
CO (1) CO2026004947A2 (es)
DO (1) DOP2026000112A (es)
IL (1) IL327830A (es)
MX (1) MX2026004682A (es)
TW (1) TW202535939A (es)
WO (1) WO2025085352A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264602A1 (en) * 2024-06-18 2025-12-26 Eli Lilly And Company PRNP RNAi AGENTS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
US11820828B2 (en) 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
US20200155702A1 (en) 2017-06-16 2020-05-21 Eli Lilly And Company Engineered Antibody Compounds and Conjuates Thereof
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
WO2021154477A1 (en) * 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
TW202246334A (zh) 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
KR20250048566A (ko) * 2022-08-08 2025-04-09 일라이 릴리 앤드 캄파니 트랜스페린 수용체 결합 단백질 및 접합체

Also Published As

Publication number Publication date
CO2026004947A2 (es) 2026-04-27
IL327830A (en) 2026-06-01
KR20260091558A (ko) 2026-06-17
MX2026004682A (es) 2026-06-01
TW202535939A (zh) 2025-09-16
WO2025085352A1 (en) 2025-04-24
AU2024362819A1 (en) 2026-05-07
DOP2026000112A (es) 2026-05-31
CN122422354A (zh) 2026-07-17

Similar Documents

Publication Publication Date Title
CO2026004947A2 (es) Proteínas de unión al receptor de transferrina y usos de estas
DOP2025000021A (es) Proteínas y conjugados de unión al receptor de transferrina
PE20231859A1 (es) Anticuerpos monoclonales anti-ccr8 y sus usos
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
CO2019004203A2 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2020002621A1 (es) Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso
López-Muñoz et al. Melatonin, neuroprotective agents and antidepressant therapy
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
BR112022007776A2 (pt) Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína
CL2025002572A1 (es) Anticuerpo anti-5t4; composición farmacéutica que lo comprende; y su uso.
MX2024002781A (es) Anticuerpos capaces de unirse a cumulo de diferenciacion 27 (cd27), variantes de los mismos y usos de los mismos.
CL2025002824A1 (es) Nueva molécula de unión
MX2021013018A (es) Formulacion de arnm.
BR112022025880A2 (pt) Administração de antagonista de cebp-beta e métodos de uso
BR112021009912A2 (pt) Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1
BR112023022999A2 (pt) Fusões peptídeo-fc para tratar distúrbios amiloides
BR112023023284A2 (pt) Anticorpos para tratamento de alfa-sinucleinopatias
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
CL2024002725A1 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
AR130145A1 (es) Proteínas y conjugados de unión al receptor de transferrina
PE20251544A1 (es) Nueva proteina de fusion especifica para cd137 y cd228
MX2022003598A (es) Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.